(RTTNews) – Novavax Inc. (NVAX) said it signed an agreement with the UK government to supply 60 million doses of the company’s COVID-19 candidate vaccine, NVXCoV2373, as early as the first quarter of 2021.
Novavax and he will collaborate in a phase 3 clinical trial in the UK to assess the effectiveness of the vaccine in the UK population, the company said in a statement.
The Phase 3 clinical trial will have random, double-blind and placebo-controlled efficacy in approximately 9,000 adults over the age of 18 to 85 in the UK. The test is expected to begin in the third quarter of this year, with the UK government supporting and providing infrastructure to Novavax to run out of the test.
In addition, Novavax said it would expand its collaboration with FUJIFILM Diosynth Biotechnologies, which will manufacture the NVX-CoV2373 antigenic from its Billingham, Stockton-on-Tees site in the United Kingdom, in addition to its sites in North Carolina and Texas in the United States.
FujiFILM Diosynth Biotechnologies in the UK is expected to produce up to 180 million consistent doses per year, further strengthening the global supply of NVX-CoV2373 in the markets.